4-(BOC-氨甲基)-N-FMOC-L-苯基丙氨酸 | 204715-91-3

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-(BOC-氨甲基)-N-FMOC-L-苯基丙氨酸
• 英文名称: Fmoc-4-(Boc-aminomethyl)-phenylalanine
• 英文别名: Fmoc-4-(Boc-aminomethyl)-L-phenylalanine；(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]propanoic acid
• CAS: 204715-91-3
• 化学式: C₃₀H₃₂N₂O₆
• mdl: MFCD01317015
• 分子量: 516.594
• InChiKey: QSPDPKLGXGMDAY-SANMLTNESA-N

物化性质

• 沸点：
  734.3±60.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  38
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Fmoc-l-4-aminomethylphenylalanine(boc)
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Fmoc-l-4-aminomethylphenylalanine(boc)
CAS number: 204715-91-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C30H32N2O6
Molecular weight: 516.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(BOC-氨甲基)-N-FMOC-L-苯基丙氨酸 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 Fmoc-para-aminomethyl-phenylalanine
  参考文献：
  名称：

  [EN] LONG-ACTING CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
  [FR] CO-AGONISTES À ACTION PROLONGÉE DES RÉCEPTEURS DU GLUCAGON ET DU GLP-1

  摘要：

  描述了长效的胰高血糖素和GLP-1受体的共激动剂。

  公开号：

  WO2019060660A1

文献信息

• Substituted indoles and methods of their use
  申请人：Hu Baihua

  公开号：US20070043101A1

  公开（公告）日：2007-02-22

  The present invention relates generally to substituted indoles and methods of using them.

  本发明一般涉及替代吲哚化合物及其使用方法。
• NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF
  申请人：Boyd A. Vincent

  公开号：US20070021434A1

  公开（公告）日：2007-01-25

  The present dislcosure provides amide-based, non-nucleoside compounds having antiviral activity against Hepacivirus, such as hepatitis C virus (HCV), methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of viral infections. The present dislcosure also provides methods for identifying amide-based, non-nucleoside compounds having antiviral activity.

  本公开提供了基于酰胺的非核苷类化合物，具有抗Hepacivirus活性，例如丙型肝炎病毒（HCV），合成这类化合物的方法和中间体，以及在各种情境中使用这些化合物的方法，包括在治疗和预防病毒感染中的应用。本公开还提供了识别具有抗病毒活性的基于酰胺的非核苷类化合物的方法。
• COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE
  申请人：Cameron Dale Russell

  公开号：US20080171783A1

  公开（公告）日：2008-07-17

  The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha and polymerase gamma.

  本公开提供了基于酰胺的非核苷类化合物，具有对内源聚合酶（如聚合酶α和聚合酶γ）的抑制活性。本公开进一步提供了用于治疗过度增殖性疾病或疾病的用途，例如良性或恶性肿瘤，更具体地是对聚合酶α和聚合酶γ抑制敏感的癌症。
• [EN] NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE DIFLUOROCÉTAMIDE UTILISÉS EN TANT QU'INHIBITEURS DE HTRA1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017148967A1

  公开（公告）日：2017-09-08

  The invention provides novel compounds having the general formula (I) wherein wherein R1, R2, R3, R4, R5, R6, R7, R3, R8, R9, R10, R11, R12 and R23 are as described herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有通式（I）的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R3、R8、R9、R10、R11、R12和R23如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。
• [EN] NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE TRIFLUOROMÉTHYLPROPANAMIDE UTILISÉS COMME INHIBITEURS DE HTRA1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018036957A1

  公开（公告）日：2018-03-01

  The invention provides novel compounds having the general formula (I) wherein R2, R3, R4, R5, R6, R7, R8, X, A and R11are as described herein, compositions including the compounds and methods of using the compounds as serine protease HtrAl inhibitors for the treatment or prophylaxis of HtrAl-mediated ocular diseases, such as wet or dry age-related macular degeneration, geographic atrophy, diabetic retinopathy, retinopathy of prematurity and polypoidal choroidal vasculopathy.

  该发明提供了具有通式（I）的新化合物，其中R2、R3、R4、R5、R6、R7、R8、X、A和R11如本文所述，包括这些化合物的组合物以及将这些化合物用作丝氨酸蛋白酶HtrAl抑制剂治疗或预防HtrAl介导的眼部疾病，如湿性或干性老年性黄斑变性、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变和多发性脉络膜脉络膜病的方法。